NCT06131554View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,480

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

July 12, 2024

Study Completion Date

December 31, 2025

Conditions
Meningococcal Meningitis
Interventions
BIOLOGICAL

batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)

1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection

BIOLOGICAL

batch 2 of MCV4

1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection

BIOLOGICAL

batch 3 of MCV4

1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection

BIOLOGICAL

Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection

Trial Locations (1)

60131

Husada Utama Hospital, Surabaya

Sponsors
All Listed Sponsors
lead

CanSino Biologics Inc.

INDUSTRY

NCT06131554 - A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years | Biotech Hunter | Biotech Hunter